Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults.
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Springer Nature
https://doi.org/10.1038/s41591-024-03431-7
https://doi.org/10.1038/s41591-024-03431-7
Abstract
Description
Acknowledgements: This study was, in part, supported by Shenzhen-Hong Kong-Macau Science and Technology Project (Category C, project no. SGDX20230821091559022) and the AIR@InnoHK Programme from the Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region. S.M.M. acknowledges support from the Natural Sciences and Engineering Research Council of Canada Discovery Grant and Alliance Grant (no. ALLRP 576914—22). A.P.G. acknowledges the Notsew Orm Sands Foundation, NIH grant no. R01 AI151176, Centers for Disease Control and Prevention (nos. U01IP001136 and U01IP001136-Suppl) and NSF Expeditions grant no. 1918784. L.W. acknowledges subcontract support from Johns Hopkins University, with funding (grant no. 75N93021C00045) from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the Government of the Hong Kong Special Administrative Region, National Institutes of Health, National Science Foundation or Centers for Disease Control and Prevention. We thank M. Xu, S. Wang, Z. Shao and R. Chen for collection of model parameters.
Funder: Notsew Orm Sands Foundation, NIH grant R01 AI151176, Centers for Disease Control and Prevention (CDC) U01IP001136, U01IP001136-Suppl, and NSF Expeditions grant 1918784.
Funder: AIR@InnoHK Programme from Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region, and Shenzhen-Hong Kong-Macau Science and Technology Project (Category C) (Project no: SGDX20230821091559022).
Funder: Natural Sciences and Engineering Research Council of Canada Discovery Grant and Alliance Grant (ALLRP 576914—22)
Funder: Johns Hopkins University with funds (Grant No. 75N93021C00045) from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services.
Funder: AIR@InnoHK Programme from Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region
Respiratory syncytial virus (RSV) causes a substantial health burden among infants and older adults. Prefusion F protein-based vaccines have shown high efficacy against RSV disease in clinical trials, offering promise for mitigating this burden through maternal and older adult immunization. Employing an individual-based model, we evaluated the impact of RSV vaccination on hospitalizations and deaths in 13 high-income countries, assuming that the vaccine does not prevent infection or transmission. Using country-specific vaccine uptake rates for seasonal influenza, we found that vaccination of older adults would prevent hospitalizations by a median of 35-64% across the countries studied here. Vaccination of pregnant women could avert infant hospitalizations by 5-50%. Reductions in RSV-related mortality mirrored those estimated for hospitalizations. While substantial hospitalization costs could be averted, the impact of vaccination depends critically on uptake rates. Enhancing uptake and accessibility is crucial for maximizing the real-world impact of vaccination on reducing RSV burden among vulnerable populations.
Funder: Notsew Orm Sands Foundation, NIH grant R01 AI151176, Centers for Disease Control and Prevention (CDC) U01IP001136, U01IP001136-Suppl, and NSF Expeditions grant 1918784.
Funder: AIR@InnoHK Programme from Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region, and Shenzhen-Hong Kong-Macau Science and Technology Project (Category C) (Project no: SGDX20230821091559022).
Funder: Natural Sciences and Engineering Research Council of Canada Discovery Grant and Alliance Grant (ALLRP 576914—22)
Funder: Johns Hopkins University with funds (Grant No. 75N93021C00045) from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services.
Funder: AIR@InnoHK Programme from Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region
Respiratory syncytial virus (RSV) causes a substantial health burden among infants and older adults. Prefusion F protein-based vaccines have shown high efficacy against RSV disease in clinical trials, offering promise for mitigating this burden through maternal and older adult immunization. Employing an individual-based model, we evaluated the impact of RSV vaccination on hospitalizations and deaths in 13 high-income countries, assuming that the vaccine does not prevent infection or transmission. Using country-specific vaccine uptake rates for seasonal influenza, we found that vaccination of older adults would prevent hospitalizations by a median of 35-64% across the countries studied here. Vaccination of pregnant women could avert infant hospitalizations by 5-50%. Reductions in RSV-related mortality mirrored those estimated for hospitalizations. While substantial hospitalization costs could be averted, the impact of vaccination depends critically on uptake rates. Enhancing uptake and accessibility is crucial for maximizing the real-world impact of vaccination on reducing RSV burden among vulnerable populations.